Newer diabetes drugs show stronger weight and blood sugar benefits in prediabetes
Key takeaway:
Newer drugs like semaglutide and tirzepatide appear best for weight and blood sugar in prediabetes.
Study at a glance
What was studied
55 studies with 16,610 adults with prediabetes testing nine medication types over 3 months to 2+ years
Study type
Meta-Analysis
duration
Long-Term (> 12 mo)
Intervention
Semaglutide, Tirzepatide, Liraglutide, Pioglitazone, Metformin, Dapagliflozin
Outcomes
Body weight, HbA1c, BMI, Fasting Plasma Glucose, Total cholesterol, Triglycerides, Renal and urinary disorders incidence
Funding
Non-industry sponsored
Main effects
Weight → ↓ (strong with semaglutide, tirzepatide)
HbA1c → ↓ (moderate with most drugs)
Cholesterol → ↓ (moderate with tirzepatide, pioglitazone)
Evidence Summary
| Intervention | Outcome | Measured Change | Study Effect |
|---|---|---|---|
 Dapagliflozin (Medications) |  Body weight (Weight & Anthropometrics) | Decrease | Limited |
Dapagliflozin (Medications) |  HbA1c (Glycemic Control) | Decrease | Limited |
Dapagliflozin (Medications) |  Renal and urinary disorders incidence (Safety) | Decrease | Strong |
Liraglutide (Medications) | Body weight (Weight & Anthropometrics) | Decrease | Limited |
Liraglutide (Medications) | HbA1c (Glycemic Control) | Decrease | Strong |
Metformin (Medications) | Body weight (Weight & Anthropometrics) | Decrease | Limited |
Metformin (Medications) | Fasting Plasma Glucose (Glycemic Control) | Decrease | Mixed |
Metformin (Medications) | HbA1c (Glycemic Control) | Decrease | Strong |
Pioglitazone (Medications) | Body weight (Weight & Anthropometrics) | Increase | Limited |
Pioglitazone (Medications) | Fasting Plasma Glucose (Glycemic Control) | Decrease | Strong |
Pioglitazone (Medications) |  Triglycerides (Metabolic Health) | Decrease | Strong |
Semaglutide (Medications) | BMI (Weight & Anthropometrics) | Decrease | Strong |
Semaglutide (Medications) | Body weight (Weight & Anthropometrics) | Decrease | Strong |
Semaglutide (Medications) | HbA1c (Glycemic Control) | Decrease | Strong |
Tirzepatide (Medications) | BMI (Weight & Anthropometrics) | Decrease | Strong |
Tirzepatide (Medications) | Fasting Plasma Glucose (Glycemic Control) | Decrease | Strong |
Tirzepatide (Medications) | Total cholesterol (Metabolic Health) | Decrease | Strong |
Unlock Full Evidence Analysis
Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.
Evidence Suggest
- Newer medications like semaglutide and tirzepatide appear to offer the best combined benefits for weight loss and blood sugar control in people with prediabetes who are overweight
- Older medications like pioglitazone lower blood sugar effectively but cause weight gain, which limits their usefulness
- Effects vary by medication type, with no single drug working best for all outcomes
Who this applies to
Adults aged 18-75 with prediabetes based on blood tests showing HbA1c of 5.7-6.4% or elevated fasting blood sugar
Keep in Mind
Most studies compared drugs to placebo rather than directly to each other, so we can't be certain which drug works best
Between the Lines
- Most studies compared to placebo, not to each other
- Results varied widely between studies
- Study lengths ranged from 3 months to 2+ years
- Most participants were of European ancestry
Unlock Full Analysis
Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.
Journal Reference
Wu Y, Wang Z, Tuersun A, et al. Efficacy and safety of anti-prediabetic drugs in patients with prediabetes: a Bayesian network meta-analysis. BMC Med. 2026;24:174. doi:10.1186/s12916-026-04705-2
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.